136 related articles for article (PubMed ID: 37967896)
1. Is Overexpression of the Plasma Membrane Transporter (
Evers R
J Pharmacol Exp Ther; 2023 Dec; 387(3):236-238. PubMed ID: 37967896
[No Abstract] [Full Text] [Related]
2. Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy.
Streby KA; Shah N; Ranalli MA; Kunkler A; Cripe TP
Pediatr Blood Cancer; 2015 Jan; 62(1):5-11. PubMed ID: 25175627
[TBL] [Abstract][Full Text] [Related]
3. The role of 131I-MIBG in high-risk neuroblastoma treatment.
Lessig MK
J Pediatr Oncol Nurs; 2009; 26(4):208-16. PubMed ID: 19726792
[TBL] [Abstract][Full Text] [Related]
4. 131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status.
Tepmongkol S; Heyman S
Med Pediatr Oncol; 1999 Jun; 32(6):427-31; discussion 432. PubMed ID: 10358701
[TBL] [Abstract][Full Text] [Related]
5. Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model.
Seo Y; Gustafson WC; Dannoon SF; Nekritz EA; Lee CL; Murphy ST; VanBrocklin HF; Hernandez-Pampaloni M; Haas-Kogan DA; Weiss WA; Matthay KK
Mol Imaging Biol; 2012 Dec; 14(6):735-42. PubMed ID: 22382618
[TBL] [Abstract][Full Text] [Related]
6. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.
Schmidt M; Simon T; Hero B; Eschner W; Dietlein M; Sudbrock F; Bongartz R; Berthold F; Schicha H
Nuklearmedizin; 2006; 45(4):145-51; quiz N39-40. PubMed ID: 16964339
[TBL] [Abstract][Full Text] [Related]
7. Targeted radiotherapy for neuroblastoma.
Meller S
Arch Dis Child; 1997 Nov; 77(5):389-91. PubMed ID: 9487957
[No Abstract] [Full Text] [Related]
8. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).
Zhou MJ; Doral MY; DuBois SG; Villablanca JG; Yanik GA; Matthay KK
Eur J Cancer; 2015 Nov; 51(16):2465-72. PubMed ID: 26254811
[TBL] [Abstract][Full Text] [Related]
9. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours.
Monsieurs MA; Thierens HM; Vral A; Brans B; De Ridder L; Dierckx RA
Nucl Med Commun; 2001 Apr; 22(4):367-74. PubMed ID: 11338046
[TBL] [Abstract][Full Text] [Related]
10. [Dosimetry for therapeutic treatment of neuroblastoma by 131I-mIBG].
Sudbrock F; Eschner W; Schmidt M; Simon T; Hero B; Schicha H
Nuklearmedizin; 2006; 45(6):254-61. PubMed ID: 17149494
[TBL] [Abstract][Full Text] [Related]
11. Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: tissue distribution, metabolism and therapeutic efficacy.
Rutgers M; Buitenhuis CK; Hoefnagel CA; Voûte PA; Smets LA
Int J Cancer; 2000 Aug; 87(3):412-22. PubMed ID: 10897048
[TBL] [Abstract][Full Text] [Related]
12. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).
Trieu M; DuBois SG; Pon E; Nardo L; Hawkins RA; Marachelian A; Twist CJ; Park JR; Matthay KK
Pediatr Blood Cancer; 2016 Mar; 63(3):436-42. PubMed ID: 26506090
[TBL] [Abstract][Full Text] [Related]
13. [(131)I] and [(125)I] metaiodobenzylguanidine therapy in macroscopic and microscopic tumors: a comparative study in SK-N-SH human neuroblastoma and PC12 rat pheochromocytoma xenografts.
Rutgers M; Buitenhuis CK; van der Valk MA; Hoefnagel CA; Voûte PA; Smets LA
Int J Cancer; 2000 Dec; 90(6):312-25. PubMed ID: 11180134
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic implications of the uptake of radiolabelled mIBG for the treatment of neuroblastoma.
O'Donoghue JA; Wheldon TE; Babich JW; Moyes JS; Barrett A; Meller ST
Prog Clin Biol Res; 1991; 366():455-61. PubMed ID: 2068160
[No Abstract] [Full Text] [Related]
15. Radiolabelled mIBG in the treatment of neuroblastoma.
Gaze MN; Wheldon TE
Eur J Cancer; 1996 Jan; 32A(1):93-6. PubMed ID: 8695251
[No Abstract] [Full Text] [Related]
16. The treatment of neuroblastoma with 131I-MIBG.
Mastrangelo R
Med Pediatr Oncol; 1987; 15(4):157-8. PubMed ID: 3657703
[No Abstract] [Full Text] [Related]
17. Dosimetric considerations in 131I-MIBG therapy for neuroblastoma in children.
Bolster AA; Hilditch TE
Br J Radiol; 1995 Nov; 68(815):1263. PubMed ID: 8542240
[No Abstract] [Full Text] [Related]
18. Hypothyroidism after treatment of metastatic neuroblastoma.
Lackner H; Urban C; Sovinz P; Nebl A; Schmidt S; Benesch M; Schwinger W
Pediatr Blood Cancer; 2010 Oct; 55(4):768. PubMed ID: 20806369
[No Abstract] [Full Text] [Related]
19. New MIBG preparation to improve targeted radiotherapy and reduce toxic side-effects in neuroblastoma patients undergoing combination treatment.
Mairs RJ; Zalutsky MR
Br J Cancer; 1995 Jul; 72(1):250. PubMed ID: 7599061
[No Abstract] [Full Text] [Related]
20. Letter to the editor.
Kono Y; Shimizu Y; Wakatsuki Y; Yasui N; Aso T; Kawamoto H; Kurihara H
Radiat Prot Dosimetry; 2015 Mar; 163(4):533-4. PubMed ID: 25227441
[No Abstract] [Full Text] [Related]
[Next] [New Search]
